Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this case-control study is to investigate glucose brain metabolism in people with multiple sclerosis and age- and sex-matched healthy controls. The main questions it aims to answer are:
Participants will come in for testing lasting approximately three hours and undergo deuterium metabolic imaging, physical function test, cognitive function test, and answer survey.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MS group | People with relapse remitting multiple sclerosis |
| |
| HC group | Healthy control participant who are age- and sex-matched to the MS group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Interventions | Other | No delivered intervention. |
|
| Measure | Description | Time Frame |
|---|---|---|
| lactate to glx ratio | Brain deuterium metabolic imaging determined lactate to glx ratio | 2 hours from enrollment to end of assessment |
| Measure | Description | Time Frame |
|---|---|---|
| Six-minute walk test | Measure of walking capacity as meters walking in six minutes | 3 hours from enrollment to end of assessment |
| 25 meter walk test | Maximal and usual walking speed over 25 feet including a 3 m measurement |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pacemaker, neurostimulator or cholera implant. Metal foreign bodies such as fragments and irremovable piercings. Unsafe medical implants (safety of heart valves, hips and the like must be confirmed).
Claustrophobia. Largest circumference including arms > 160 cm
Not provided
Not provided
The study seeks to include people with relapsing remitting multiple sclerosis that are otherwise healthy and age- and sex-matched healthy control participants.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tobias Gæmelke, PhD-stud | Contact | 4528264508 | gaemelke@ph.au.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University | Recruiting | Aarhus C | 8000 | Denmark |
Due to the European Unions General Data Protection Regulation.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020529 | Multiple Sclerosis, Relapsing-Remitting |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 hours from enrollment to end of assessment |
| Six-spot-step-test | Fastes time to kick six block away from six markings on the floor approximatly 1 meter from another in a zig-zag patteren. | 3 hours from enrollment to end of assessment |
| Handgrip strength | Handgrip dynamometry | 3 hours from enrollment to end of assessment |
| 5-sit-to-stand | Time to perform five sit to stand. | 3 hours from enrollment to end of assessment |
| Processing speed - Selective reminding test | Symbol digit modality test, number of symbols translated in 90 s | 3 hours from enrollment to end of assessment |
| Memory function - Symbol digit modality test | Symbol digit modality test
| 3 hours from enrollment to end of assessment |
| Glukose level | From blood sample | 3 hours from enrollment to end of assessment |
| Lactat level | From blood sample | 3 hours from enrollment to end of assessment |
| Glucose uptake | Brain deuterium metabolic imaging demined glucose uptake measured by glucose to DHO + glucose ratio | 2 hours from enrollment to end of assessment |
| glucose to glx ratio | Brain deuterium metabolic imaging demined glucose to glx ratio | 2 hours from enrollment to end of assessment |
| Clinical information on multiple sclerosis - Disease modifying treatment | Information on current disease modifying treatment are exacted from the hospital patient record | 7 days from enrollment to end of assessment |
| Clinical information on multiple sclerosis - Time since diagnosis | Information on time since diagnosis are exacted from the hospital patient record | 7 days from enrollment to end of assessment |
| Modified Fatigue Impact Scale | A 29-item questionnaire measuring the impact of multiple sclerosis on the patient. With a minimum score of 29 and a maximum of 116, a higher score indicates a worse outcome. | 7 days from enrollment to end of assessment |
| Clinical information on multiple sclerosis - Expanded disability status score | Information on expanded disability status score is exacted from the hospital patient record. The expanded disability status score is a physician rating of disease severity from 0-10 with a higher score indicating higher disability. | 7 days from enrollment to end of assessment |
| Multiple Sclerosis Impact Scale | A 21-item questionnaire measuring the impact of multiple sclerosis on the patient. With a minimum score of 0 and a maximum of 84, a higher score indicates a worse outcome. | 7 days from enrollment to end of assessment |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |